Overall, we demonstrate the prophylactic and therapeutic effects of NaNO3 on metabolic syndrome and reveal a new macrophage rebalancing strategy involving NaNO3 through a novel sialin pathway. The gene discussed is SLC17A5; the disease is metabolic syndrome.